Illustration, AI-generated from the story text. Tap a panel to read the story through it.
Tempus AI, which sells cancer genomic testing and licenses the de-identified clinical data behind it to drug makers, reported third-quarter revenue of $411.5 million on Monday, up 23%. Adjusted was $25.6 million against $1.5 million a year earlier.
Oncology test volume grew 32% and the data business 33%, and the company said data licensing bookings have passed $550 million this year after an October agreement with Bristol Myers Squibb.
It raised its 2026 revenue forecast to $1.60 billion to $1.605 billion. The shares closed up 8.7% on a day the Nasdaq fell 1.1%.
Tempus AI raises its forecast as data licensing passes $550 million
Tempus AI, which sells cancer genomic testing and licenses the de-identified clinical data behind it to drug makers, reported third-quarter revenue of $411.5 million on Monday, up 23%. Adjusted EBITDA was $25.6 million against $1.5 million a year earlier. Oncology test volume grew 32% and the data business 33%, and the company said data licensing bookings have passed $550 million this year after an October agreement with Bristol Myers Squibb. It raised its 2026 revenue forecast to $1.60 billion to $1.605 billion. The shares closed up 8.7% on a day the Nasdaq fell 1.1%. SourcesAC
Sources
- ATempus AI Q3 2026 results, Form 8-K exhibit 99.1 (SEC EDGAR)sec.gov
- CTech Stocks Pull the Nasdaq Lower in the Stock Market Today Live, November 2, 2026 (Stocktitan)stocktitan.net
This story ran in the Afternoon Brief of November 2nd 2026.